Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses COLL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named COLL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| David Dieter | $384,615 | $0 | $3,189,732 | $0 | $277,183 | $0 | $18,562 | $3,870,092 |
| Executive Vice President and General Counsel | ||||||||
| Colleen Tupper | 559,340 | 0 | 2,484,486 | 0 | 449,289 | 0 | 21,940 | 3,515,055 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Scott Dreyer | 523,236 | 0 | 2,160,473 | 0 | 335,563 | 0 | 21,940 | 3,041,212 |
| Executive Vice President and Chief Commercial Officer | ||||||||
| Shirley Kuhlmann | 115,522 | 0 | 1,966,013 | 0 | 0 | 0 | 702,048 | 2,783,583 |
| Former Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | ||||||||
| Thomas Smith | 492,959 | 0 | 1,620,314 | 0 | 315,195 | 0 | 17,540 | 2,446,008 |
| Executive Vice President and Chief Medical Officer | ||||||||
| Vikram Karnani | 875,000 | 0 | 0 | 0 | 835,406 | 0 | 5,440 | 1,715,846 |
| President and Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| David Dieter | $3,870,092 | — | — | — |
| Colleen Tupper | 3,515,055 | — | — | — |
| Scott Dreyer | 3,041,212 | — | — | — |
| Shirley Kuhlmann | 2,783,583 | — | — | — |
| Thomas Smith | 2,446,008 | — | — | — |
| Vikram Karnani | 1,715,846 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Garen Bohlin | Director | 2026-05-11 | D | 8,700 | $37 | $323,491 | Common | Form 4 ↗ |
| Garen Bohlin | Director | 2026-05-11 | D | 8,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Garen Bohlin | Director | 2026-05-11 | A | 8,700 | 16 | 143,463 | Common | Form 4 ↗ |
| Nancy Lurker | Director | 2026-05-13 | D | 4,500 | 36 | 161,861 | Common | Form 4 ↗ |
| John Freund | Director | 2026-05-14 | D | 8,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy Lurker | Director | 2026-05-14 | A | 8,741 | 0 | 0 | Common | Form 4 ↗ |
| John Freund | Director | 2026-05-14 | A | 8,700 | 16 | 143,463 | Common | Form 4 ↗ |
| Gino Santini | Director | 2026-05-14 | A | 8,741 | 0 | 0 | Common | Form 4 ↗ |
| John Freund | Director | 2026-05-14 | A | 8,741 | 0 | 0 | Common | Form 4 ↗ |
| Donovan Michael Glancy | Director | 2026-05-14 | A | 17,482 | 0 | 0 | Common | Form 4 ↗ |
| Rita Balice-Gordon | Director | 2026-05-14 | A | 8,741 | 0 | 0 | Common | Form 4 ↗ |
| Garen Bohlin | Director | 2026-05-14 | A | 8,741 | 0 | 0 | Common | Form 4 ↗ |
| John Freund | Director | 2026-05-14 | D | 4,127 | 35 | 142,547 | Common | Form 4 ↗ |
| Carlos Paya | Director | 2026-05-14 | A | 8,741 | 0 | 0 | Common | Form 4 ↗ |
| John Freund | Director | 2026-05-18 | D | 20 | 34 | 681 | Common | Form 4 ↗ |
| Gino Santini | Director | 2026-06-08 | A | 8,700 | 16 | 143,463 | Common | Form 4 ↗ |
| Gino Santini | Director | 2026-06-08 | D | 8,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Thomas Smith | PSU | 2025-02-10 | 2,894 | 5,787 | — | 11,574 | $253,934 |
| Shirley Kuhlmann | RSU | 2025-02-10 | — | — | 40,965 | — | 1,250,252 |
| Thomas Smith | PSU | 2025-02-10 | 1,447 | 2,894 | — | 5,788 | 111,448 |
| Scott Dreyer | PSU | 2025-02-10 | — | 3,858 | — | 7,716 | 150,308 |
| Shirley Kuhlmann | PSU | 2025-02-10 | 1,756 | 3,511 | — | 7,022 | 136,789 |
| Thomas Smith | PSU | 2025-02-10 | 1,447 | 2,894 | — | 5,788 | 111,766 |
| Shirley Kuhlmann | PSU | 2025-02-10 | 1,756 | 3,511 | — | 7,022 | 135,209 |
| David Dieter | PSU | 2025-03-17 | 2,934 | 5,867 | — | 11,734 | 220,893 |
| Scott Dreyer | RSU | 2025-02-10 | — | — | 45,016 | — | 1,373,888 |
| Colleen Tupper | RSU | 2025-02-10 | — | — | 51,768 | — | 1,579,959 |
| Scott Dreyer | PSU | 2025-02-10 | — | 3,858 | — | 7,716 | 148,996 |
| Scott Dreyer | PSU | 2025-02-10 | — | 3,858 | — | 7,716 | 148,572 |
| Thomas Smith | RSU | 2025-02-10 | — | — | 33,762 | — | 1,030,416 |
| Colleen Tupper | PSU | 2025-02-10 | 2,219 | 4,437 | — | 8,874 | 172,866 |
| Thomas Smith | PSU | 2025-02-10 | 1,447 | 2,894 | — | 5,788 | 112,750 |
| Colleen Tupper | PSU | 2025-02-10 | 2,219 | 4,437 | — | 8,874 | 171,357 |
| David Dieter | RSU | 2025-03-17 | — | — | 68,449 | — | 2,030,882 |
| David Dieter | PSU | 2025-03-17 | 2,934 | 5,867 | — | 11,734 | 218,956 |
| David Dieter | PSU | 2025-03-17 | 2,934 | 5,867 | — | 11,734 | 220,541 |
| Scott Dreyer | PSU | 2025-02-10 | 3,860 | 7,719 | — | 15,438 | 338,710 |
| Shirley Kuhlmann | PSU | 2025-02-10 | 1,756 | 3,511 | — | 7,022 | 135,595 |
| David Dieter | PSU | 2025-03-17 | 5,867 | 11,734 | — | 23,468 | 498,460 |
| Shirley Kuhlmann | PSU | 2025-02-10 | 3,512 | 7,023 | — | 14,046 | 308,169 |
| Colleen Tupper | PSU | 2025-02-10 | 4,438 | 8,875 | — | 17,750 | 389,435 |
| Colleen Tupper | PSU | 2025-02-10 | 2,219 | 4,437 | — | 8,874 | 170,869 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Thomas Smith | $1,030,416 | $589,898 | $0 | 36.4% |
| Shirley Kuhlmann | 1,250,252 | 715,762 | 0 | 36.4% |
| Scott Dreyer | 1,373,888 | 786,586 | 0 | 36.4% |
| David Dieter | 2,030,882 | 1,158,850 | 0 | 36.3% |
| Colleen Tupper | 1,579,959 | 904,527 | 0 | 36.4% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Dieter | PSU | 46,936 | — | $2,173,137 |
| Thomas Smith | RSU | 24,934 | — | 1,154,444 |
| Scott Dreyer | RSU | 28,334 | — | 1,311,864 |
| Scott Dreyer | RSU | 41,918 | — | 1,940,803 |
| Thomas Smith | RSU | 29,525 | — | 1,367,008 |
| David Dieter | RSU | 77,454 | — | 3,586,120 |
| Colleen Tupper | PSU | 20,880 | — | 966,744 |
| Scott Dreyer | RSU | 13,125 | — | 607,688 |
| Vikram Karnani | RSU | 112,010 | — | 5,186,063 |
| Colleen Tupper | RSU | 42,647 | — | 1,974,556 |
| Vikram Karnani | Option | 97,758 | 31.41 | — |
| Vikram Karnani | PSU | 169,556 | — | 7,850,443 |
| Colleen Tupper | RSU | 58,578 | — | 2,715,161 |
| Colleen Tupper | PSU | 35,498 | — | 1,643,557 |
| Colleen Tupper | RSU | 32,867 | — | 1,521,742 |
| Colleen Tupper | RSU | 13,125 | — | 607,688 |
| Scott Dreyer | RSU | 50,938 | — | 2,358,429 |
| Thomas Smith | RSU | 38,204 | — | 1,768,845 |
| Scott Dreyer | PSU | 30,870 | — | 1,429,281 |
| Thomas Smith | PSU | 23,150 | — | 1,071,845 |
| Scott Dreyer | PSU | 18,000 | — | 833,400 |
| Thomas Smith | PSU | 15,840 | — | 733,392 |
Our executive compensation programs are designed to reward the achievement of our short- and long-term strategic objectives and to drive the creation of long-term shareholder value by successfully executing our business strategy.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-14 | 26,313,792 | 1,100,723 | 5,646 | 95.98% | Passed |
| 2025 | 2025-05-15 | 22,867,414 | 2,233,541 | 2,544,266 | 91.1% | Passed |
| 2024 | 2024-05-16 | 28,311,783 | 350,755 | 36,150 | 98.78% | Passed |
| 2023 | 2023-05-18 | 27,953,926 | 315,383 | 90,502 | 98.88% | Passed |
| 2022 | 2022-05-23 | 28,337,587 | 643,459 | 35,822 | 97.78% | Passed |
| 2021 | 2021-05-20 | 29,689,528 | 353,660 | 46,170 | 98.82% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-14 | 95.98%a |
| 2025 | 2025-05-15 | 91.1%b |
| 2024 | 2024-05-16 | 98.78%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast either " FOR " or " AGAINST " this proposal and, thus, will have no impact on the outcome of Executive Vice President, General Counsel and Corporate Secretary • Mr.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast either " FOR " or " AGAINST " this proposal and, thus, will have no impact on the outcome of eral Counsel since March 2025.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast either " FOR " or " AGAINST " this proposal and, thus, will have no impact on the outcome of erations;”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 8 : 1 |
|---|---|
| CEO total compensation | $1,715,846 |
| Median employee compensation | $221,391 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Nancy LurkerIndependent · Compliance (Chair) · Compensation | $62,893 | $680,883 | $0 | $0 | $0 | $743,776 |
| Carlos PayaIndependent · Transaction (Chair) · Nominating and Corporate Governance | 34,601 | 574,536 | 0 | 0 | 0 | 609,137 |
| Gino SantiniIndependent · Board Chair · Compensation · Transaction | 113,695 | 287,268 | 0 | 0 | 0 | 400,963 |
| John FreundIndependent · Compensation (Chair) · Audit | 80,000 | 287,268 | 0 | 0 | 0 | 367,268 |
| Garen BohlinIndependent · Audit (Chair) · Compliance | 79,371 | 287,268 | 0 | 0 | 0 | 366,639 |
| John FallonIndependent · Nominating and Corporate Governance (Chair) · Audit · Compliance · Not standing for re-election | 79,000 | 287,268 | 0 | 0 | 0 | 366,268 |
| Rita Balice-GordonIndependent · Nominating and Corporate Governance · Transaction | 55,000 | 287,268 | 0 | 0 | 0 | 342,268 |
| Michael HeffernanIndependent · Departed during FY | 41,099 | 147,106 | 0 | 0 | 0 | 188,205 |
| Gwen MelincoffIndependent · Departed during FY | 20,549 | — | 0 | 0 | 0 | 20,549 |
| Michael DonovanIndependent · Audit · Compliance · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Vikram KarnaniEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $275,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 20,000 / 10,000 |
| Stock ownership guideline | 3x annual cash retainer for non-employee directors |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $566,208 |
| Equity awards (grant-date value) | $2,838,865 |
| All other compensation | $0 |
| Total cost of the board | $3,405,073 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Collegium Pharmaceutical names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Collegium Pharmaceutical.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | BioCryst Pharmaceuticals, Inc. | 2025 | Jon Stonehouse | $728,466 | $0 | $11,132,458 | $1,052,633 | $12,951,082 |
| 2 | ANI Pharmaceuticals, Inc. | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 3 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 4 | Amphastar Pharmaceuticals, Inc. | 2025 | Jack Yongfeng Zhang | 950,911 | 3,301,981 | 3,302,024 | 361,000 | 8,309,350 |
| 5 | ACADIA Pharmaceuticals, Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 6 | Catalyst Pharmaceuticals, Inc. | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 7 | Collegium Pharmaceutical | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Collegium Pharmaceutical | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| ACADIA Pharmaceuticals, Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | FW Cook |
| Amicus Therapeutics, Inc. | 108% | Options 33 · RSU 33 · PSU 33 | Yes — TSR Goal | Pay Governance |
| Amphastar Pharmaceuticals, Inc. | not disclosed | Options 50 · RSU 50 | not disclosed | Willis Towers Watson (WTW) |
| ANI Pharmaceuticals, Inc. | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| BioCryst Pharmaceuticals, Inc. | 170% | not disclosed | not disclosed | Aon Human Capital Solutions (division of Aon plc) |
| Catalyst Pharmaceuticals, Inc. | 105% | not disclosed | not disclosed | Mercer LLC (a business of Marsh McLennan) |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, David Dieter | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Summary Compensation Table”. As printed: 3,870,092. Filing ↗machine: r8 · c48 · span 801432–801441 |
| 2 | Section 01, Colleen Tupper | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Summary Compensation Table”. As printed: 3,515,055. Filing ↗machine: r5 · c48 · span 790338–790347 |
| 3 | Section 01, Scott Dreyer | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Summary Compensation Table”. As printed: 3,041,212. Filing ↗machine: r11 · c48 · span 812129–812138 |
| 4 | Section 01, Shirley Kuhlmann | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Summary Compensation Table”. As printed: 2,783,583. Filing ↗machine: r17 · c48 · span 834020–834029 |
| 5 | Section 01, Thomas Smith | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Summary Compensation Table”. As printed: 2,446,008. Filing ↗machine: r14 · c48 · span 823230–823239 |
| 6 | Section 01, Vikram Karnani | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Summary Compensation Table”. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 7 | Section 03, Thomas Smith PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r25 · c20 · span 915279–915286 |
| 8 | Section 03, Shirley Kuhlmann RSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r32 · c20 · span 932312–932321 |
| 9 | Section 03, Thomas Smith PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r23 · c20 · span 910352–910359 |
| 10 | Section 03, Scott Dreyer PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r16 · c20 · span 893172–893179 |
| 11 | Section 03, Shirley Kuhlmann PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r28 · c20 · span 922788–922795 |
| 12 | Section 03, Thomas Smith PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r24 · c20 · span 912815–912822 |
| 13 | Section 03, Shirley Kuhlmann PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r29 · c20 · span 925251–925258 |
| 14 | Section 03, David Dieter PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r12 · c20 · span 883384–883391 |
| 15 | Section 03, Scott Dreyer RSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r20 · c20 · span 902696–902705 |
| 16 | Section 03, Colleen Tupper RSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r8 · c20 · span 873265–873274 |
| 17 | Section 03, Scott Dreyer PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r18 · c20 · span 898098–898105 |
| 18 | Section 03, Scott Dreyer PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r17 · c20 · span 895635–895642 |
| 19 | Section 03, Thomas Smith RSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r26 · c20 · span 917413–917422 |
| 20 | Section 03, Colleen Tupper PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r4 · c20 · span 863741–863748 |
| 21 | Section 03, Thomas Smith PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r22 · c20 · span 907889–907896 |
| 22 | Section 03, Colleen Tupper PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r6 · c20 · span 868667–868674 |
| 23 | Section 03, David Dieter RSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r14 · c20 · span 887985–887994 |
| 24 | Section 03, David Dieter PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r10 · c20 · span 878454–878461 |
| 25 | Section 03, David Dieter PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r11 · c20 · span 880919–880926 |
| 26 | Section 03, Scott Dreyer PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r19 · c20 · span 900562–900569 |
| 27 | Section 03, Shirley Kuhlmann PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r30 · c20 · span 927714–927721 |
| 28 | Section 03, David Dieter PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r13 · c20 · span 885850–885857 |
| 29 | Section 03, Shirley Kuhlmann PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r31 · c20 · span 930178–930185 |
| 30 | Section 03, Colleen Tupper PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r7 · c20 · span 871131–871138 |
| 31 | Section 03, Colleen Tupper PSU | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t69 · r5 · c20 · span 866204–866211 |
| 32 | Section 07, pay ratio | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “CEO Pay Ratio”. As printed: 8 : 1. Filing ↗machine: span 1114023–1114024 |
| 33 | Section 08, Nancy Lurker | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 743,776. Filing ↗machine: t50 · r7 · c8 · span 487538–487545 |
| 34 | Section 08, Carlos Paya | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 609,137. Filing ↗machine: t50 · r9 · c8 · span 490857–490864 |
| 35 | Section 08, Gino Santini | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 400,963. Filing ↗machine: t50 · r10 · c8 · span 492323–492330 |
| 36 | Section 08, John Freund | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 367,268. Filing ↗machine: t50 · r5 · c8 · span 484221–484228 |
| 37 | Section 08, Garen Bohlin | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 366,639. Filing ↗machine: t50 · r3 · c8 · span 481281–481288 |
| 38 | Section 08, John Fallon | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 366,268. Filing ↗machine: t50 · r4 · c8 · span 482751–482758 |
| 39 | Section 08, Rita Balice-Gordon | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 342,268. Filing ↗machine: t50 · r2 · c8 · span 479785–479792 |
| 40 | Section 08, Michael Heffernan | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 188,205. Filing ↗machine: t50 · r6 · c8 · span 485885–485892 |
| 41 | Section 08, Gwen Melincoff | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 20,549. Filing ↗machine: t50 · r8 · c2 · span 488380–488386 |
| 42 | Section 08, Michael Donovan | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 43 | Section 08, Vikram Karnani | DEF 14A | 2026-04-07 | 0001628280-26-024063 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 44 | Section 02, Garen Bohlin 2026-05-11 | Form 4 | 2026-05-13 | 0001254705-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Garen Bohlin 2026-05-11 | Form 4 | 2026-05-13 | 0001254705-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Garen Bohlin 2026-05-11 | Form 4 | 2026-05-13 | 0001254705-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Nancy Lurker 2026-05-13 | Form 4 | 2026-05-15 | 0001450485-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, John Freund 2026-05-14 | Form 4 | 2026-05-18 | 0001296771-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Nancy Lurker 2026-05-14 | Form 4 | 2026-05-18 | 0001450485-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, John Freund 2026-05-14 | Form 4 | 2026-05-18 | 0001296771-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Gino Santini 2026-05-14 | Form 4 | 2026-05-18 | 0001276038-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, John Freund 2026-05-14 | Form 4 | 2026-05-18 | 0001296771-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Donovan Michael Glancy 2026-05-14 | Form 4 | 2026-05-18 | 0002134015-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Rita Balice-Gordon 2026-05-14 | Form 4 | 2026-05-18 | 0001825625-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Garen Bohlin 2026-05-14 | Form 4 | 2026-05-18 | 0001254705-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, John Freund 2026-05-14 | Form 4 | 2026-05-18 | 0001296771-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Carlos Paya 2026-05-14 | Form 4 | 2026-05-18 | 0001606244-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, John Freund 2026-05-18 | Form 4 | 2026-05-20 | 0001296771-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Gino Santini 2026-06-08 | Form 4 | 2026-06-10 | 0001276038-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Gino Santini 2026-06-08 | Form 4 | 2026-06-10 | 0001276038-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 06, 2026 vote | Form 8-K | 2026-05-15 | 0001104659-26-062536 | Item 5.07 · say-on-pay result. As reported: 95.98% (votes for as printed: 26,313,792). Filing ↗ |
| 62 | Section 06, 2025 vote | Form 8-K | 2025-05-19 | 0001104659-25-050435 | Item 5.07 · say-on-pay result. As reported: 91.1% (votes for as printed: 22,867,414). Filing ↗ |
| 63 | Section 06, 2024 vote | Form 8-K | 2024-05-20 | 0001104659-24-063396 | Item 5.07 · say-on-pay result. As reported: 98.78% (votes for as printed: 28,311,783). Filing ↗ |
| 64 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 65 | Section 09b board cost (computed) | Computed | — | computed | Cash 566,208 + equity 2,838,865 + all other 0 = 3,405,073, summed across the director compensation table rows.machine: formula: Σ = 3,405,073 |
| 66 | BioCryst Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026822 | CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266 |
| 67 | ANI Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001023024-26-000039 | CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. Filing ↗machine: r2 · c48 · span 484144–484154 |
| 68 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736127–736137 |
| 69 | Amphastar Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-13 | 0001297184-26-000023 | CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. Filing ↗machine: span 722923–722932 |
| 70 | ACADIA Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals, Inc.'s own proxy. As printed: 8,256,518. Filing ↗machine: t33 · span 1170878–1170887 |
| 71 | Catalyst Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-11 | 0001193125-25-079097 | CEO total compensation as printed in Catalyst Pharmaceuticals, Inc.'s own proxy. As printed: 7,774,160. Filing ↗machine: r3 · c31 · span 285833–285842 |
| 72 | Collegium Pharmaceutical (subject), Section 10b CEO total | DEF 14A | 2026-04-07 | 0001628280-26-024063 | CEO total compensation as printed in Collegium Pharmaceutical's own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 73 | Section 10a, ANI Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001023024-26-000039 | ANI Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Collegium Pharmaceutical. Filing ↗ |
| 74 | Section 10a, ACADIA Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Collegium Pharmaceutical. Filing ↗ |
| 75 | Section 10a, Catalyst Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-25-079097 | Catalyst Pharmaceuticals, Inc. names Collegium Pharmaceutical in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 76 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Collegium Pharmaceutical. Filing ↗ |
| 77 | Section 10a, Amphastar Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001297184-26-000023 | Amphastar Pharmaceuticals, Inc. names Collegium Pharmaceutical in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 78 | Section 10a, BioCryst Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-026822 | BioCryst Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Collegium Pharmaceutical. Filing ↗ |